Participated · Series C · Aug 2026

Bridge to Life develops organ preservation solutions and perfusion technologies, including the VitaSmart Hypothermic Oxygenated Perfusion (HOPE) System and the Belzer UW preservation franchise. The VitaSmart system received FDA De Novo clearance in January 2026 and the company reports rapid adoption by leading academic transplant centers, master service agreements, and repeat orders. Bridge to Life is advancing a science-based organ viability assessment tool that is currently investigational and not cleared for commercial sale. The company plans to expand its portfolio beyond liver transplantation into additional organ applications over the next three years and is developing next-generation closed systems to streamline transport. The recent financing was used both to accelerate commercial rollout in the U.S. and to refinance existing debt, reflecting the company’s shift to a fully commercial organization. Bridge to Life is headquartered in Duluth, Georgia.

Participated · Equity · Feb 2025

OrganOx, spun out of the University of Oxford in 2008 and led by Oern R. Stuge, MD, MBA, develops the metra normothermic machine perfusion (NMP) platform to improve outcomes for patients with acute or chronic organ failure. The metra system is approved in the U.S., Europe, Canada and Australia and has been used in over 5,000 liver transplants to keep donor livers metabolically active, extend preservation times and enable functional assessment prior to transplant. The company is commercial stage and focuses on scaling its metra platform across global organ-technology markets. OrganOx says it will use new funding to expand operations and accelerate development efforts. Recent financings include a private placement first close and a primary/secondary equity raise intended to accelerate growth opportunities for the metra platform. OrganOx is an Oxford, UK–based commercial-stage organ medical technology company spun out of the University of Oxford in 2008 and led by Oern R. Stuge, MD, MBA, Executive Chairman. Its core product is the metra® normothermic machine perfusion (NMP) platform, approved in the U.S., Europe, Canada, and Australia, which keeps donor livers metabolically active outside the body for functional assessment prior to transplant. The metra® has been utilized in over 5,000 liver transplants to date, contributing to increased organ availability. The company also has an investigational metra® technology for kidney transplants that is expected to soon begin U.S. clinical trials and plans a first-in-human study with eGenesis combining metra® with genetically engineered porcine livers to support patients with acute-on-chronic liver failure. OrganOx recently closed a $142M equity financing and intends to use the funds to accelerate growth opportunities for its metra® platform in the global organ technology market. OrganOx develops metra, an automated normothermic machine perfusion (NMP) device that preserves donor livers in a functioning state for up to 24 hours and enables continuous monitoring and viability assessment. The metra platform provides surgeons with evidence-based data to decide whether to transplant donor organs and has enabled transplant of previously declined livers. The device is commercially available in Europe (CE Mark) and the United States. Since inception, OrganOx's NMP technology has supported over 2,500 liver transplants worldwide. The company was founded in 2008 by Professors Peter Friend and Constantin Coussios and is led by CEO Craig Marshall. OrganOx recently raised new growth funding to support its commercial and clinical expansion.

Participated · Series C · Aug 2024

Caresyntax offers a vendor-neutral precision surgery platform led by CEO Dennis Kogan. Its proprietary software and AI captures and analyzes large volumes of video, audio, images, device, clinical and operational data in and around the operating room to deliver actionable insights, meta-data and real-world evidence. The software and automation platform can be used live during procedures and accessed by users outside the OR via secured dedicated cloud and telehealth links. The platform aims to help surgeons and care teams improve patient outcomes, enable hospital administrators to use resources more efficiently, assist medical device companies to advance products, and support insurers in understanding and controlling risks and enabling value-based contracts. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide. The company raised $180M in Series C financing and intends to use the funds to expand operations and its development efforts. Caresyntax provides a digital surgery platform that uses proprietary software and artificial intelligence to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. The platform delivers actionable insights for care teams and longer-term analytics for stakeholders such as surgeons, and offers virtual, real-time access to outside experts. Caresyntax's software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company plans to use new funds to continue developing its platform and to advance new data solutions that support value-based care providers. The product emphasis is on improving patient outcomes through immediate and longer-term insights derived from real-world OR data. The company was founded by Dennis Kogan and Björn von Siemens. Caresyntax provides an enterprise-grade digital surgery platform that uses proprietary software and AI to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. Its platform delivers real-world evidence that care teams can use live during procedures via a telehealth link and post-procedure for benchmarking and improvement. Hospitals can use the platform to manage surgical resources more efficiently, medical device companies can advance products, and insurers can better understand risk. The software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company announced the acquisition of Syus at the close of 2019, extending its hospital footprint and analytics capabilities. Caresyntax intends to use the new funding to accelerate expansion in key markets, further R&D of its AI analytics, build out its platforms, and grow its employee base. caresyntax provides surgical intelligence and automation solutions that leverage IoT, analytics and AI to integrate data from medical devices, EHRs and other OR sources into a unified platform. Its offerings automate clinical and operational decision support for surgical teams and support outcome contributors across risk-bearing contracts. The company says its technologies are used in more than 7,000 operating rooms worldwide and support over 10 million procedures per year. Recent partnerships with organizations including Mitsubishi’s MC Healthcare, Barco Healthcare, Insel Gruppe AG and University of Wisconsin–Madison aim to expand R&D and global reach. caresyntax plans to use new capital to accelerate domestic and international growth and to further develop and deploy its surgical intelligence and automation technologies. The company works with providers, insurers and device vendors to inform device improvements, support data-driven underwriting and enable value-based contracting. Caresyntax provides a vendor-neutral platform that aggregates structured and unstructured data from operating room devices, electronic health records and other sources into unified dashboards for surgeons and hospital decision makers. Its offerings include PRIME365 OR integration and qvident surgical performance management software, which aim to reduce documentation time, automate workflows, and generate quality data for training and decision support. The company emphasizes granular analysis of surgical variation to recommend fixes that reduce readmissions, improve patient safety and streamline clinical workflows. Caresyntax reports an installed base of more than 6,000 operating rooms, supports over 10 million procedures per year and generates roughly 100 petabytes of high-fidelity data annually. It was launched in 2013 in Germany and established full-time North American operations and a headquarters in Boston in October. The company says it will use the new financing to grow its U.S. business and to develop machine learning and value-added applications for surgical risk management.

Led · Series C · May 2024

Natural Cycles provides a direct-to-consumer contraceptive app (NC°) that uses an algorithm driven by body temperature to determine each user's daily fertility status. Users can enter thermometer readings manually or sync overnight temperature trends from an Oura Ring or Apple Watch. The app has been used by more than three million users and holds regulatory clearances in the United States (FDA), Europe (TÜV SÜD), Canada (Health Canada), Australia (TGA), Singapore (HSA), and South Korea (MFDS). Founded in 2013 and based in Stockholm, Sweden, Natural Cycles recently launched NC° Postpartum and offers multiple modes including NC° Birth Control, NC° Plan Pregnancy, and NC° Follow Pregnancy. The company plans to invest in commercial acceleration, new product development, and healthcare reimbursement automation. The business also secured a revolving debt facility as part of its recent financing. Natural Cycles develops a fertility‑tracking app and algorithm that uses body temperature and other fertility indicators to predict menstrual cycles and fertility windows. The company says its app has helped millions of women worldwide. Natural Cycles' algorithm will be integrated with Samsung’s Galaxy Watch5 infrared skin‑temperature sensor to enable overnight, temperature‑based cycle tracking. According to Samsung, the data are encrypted and stored on the device and used to power the Samsung Health Cycle Tracking feature. The skin temperature–based tracking capability is slated to roll out across 32 countries (including markets in North America, Europe and Asia) and arrive on the Galaxy Watch5 and Watch5 Pro within the second quarter. The article notes broader cautions — echoed by Apple — that temperature‑based tracking should not be used as birth control or to diagnose medical conditions and that overnight readings can be affected by factors like the sleep environment. Natural Cycles offers a subscription fertility-tracking app that uses user-input daily basal body temperature (measured to two decimals) and algorithms to predict fertile and non-fertile days, presenting results in a red/green calendar. The company includes a basal thermometer in its annual subscription and says its algorithm models individual uncertainty to adapt to irregular cycles and missing inputs. Natural Cycles reports 500,000+ users across roughly 160 countries, an average user age of 29, and a first-year renewal rate of about 60%. The team is roughly 40 people (including seven physicist PhDs) and plans to grow headcount to 100–120 within a year. The company has published studies claiming 93% typical-use efficacy and cites an oversight body–reviewed method-failure rate of 0.5% per year, but its efficacy claims have drawn criticism because it has not completed randomized controlled trials. Natural Cycles secured EU certification for use as a contraceptive in February 2017 and has applied to the FDA; planned product priorities include clinical research, product development and international expansion, with the US and UK cited as key markets. Natural Cycles offers a subscription app that asks users to input daily basal body temperature and uses algorithmic adjustments to identify fertile windows, presenting risk days with a red/green color code. The company requires manual temperature entry (a planned wireless thermometer was put on hold) and emphasizes clinical research to validate accuracy. It reports more than 100,000 active users across 161 countries and $2 million in revenue in 2015, its first full year of trading, and captured about 4% of the Swedish contraception market within 18 months. Founders Dr. Elina Berglund and Dr. Raoul Scherwitzl, a wife-and-husband physicist duo, launched the company in June 2013 and expanded from the Nordics into the U.K. in October 2014. Natural Cycles has run a 4,000‑woman study using Pearl Index metrics (typical‑use failure ~7 per 100 vs ~9 per 100 for the pill; perfect‑use 5 per 1,000 vs 3 per 1,000 for the pill) and plans more clinical work, including a randomized control study versus the contraceptive pill. The team plans to use new funding to deepen research, expand the team and push into the U.S. market while continuing to develop services around contraceptive choice and fertility.

Led · Equity · Sep 2023

Founded in 2009 by Dr Karl Tryggvason and Kristian Tryggvason, BioLamina produces full-length, chemically defined, animal origin-free human recombinant laminins (Biolaminin®) used to support controlled cell culture systems. Its substrates are designed to enable reliable growth and differentiation of pluripotent stem cells and other primary cells and are used in cell therapy development, including phase I–III clinical trials. The company emphasizes scalable, high-quality cell culture solutions to improve consistency for cell therapies and drug testing. BioLamina recently secured a €20 million venture debt loan from the European Investment Bank to expand manufacturing capacity, optimise processes, broaden its product portfolio and strengthen its technological base. The financing is intended to extend the company’s funding runway while minimising immediate equity dilution.